Consensus GSK plc

Equities

GSK

GB00BN7SWP63

Pharmaceuticals

Market Closed - London S.E. Other stock markets 11:35:18 2025-12-12 am EST			5-day change	1st Jan Change
1,824.50 ^GBX	+0.19%		+1.08%	+35.50%

Dec. 12	US FDA approves Innoviva's oral antibiotic for gonorrhea	RE
Dec. 12	Surprise UK GDP Contraction Keeps FTSE 100 in the Red	MT

Evolution of the Average Target: GSK plc

Evolution of the Target Price: GSK plc

Changes in Analyst Recommendations: GSK plc

2406fc6d1ab16e52b237cde5fe.mclQmWIpzfDZXFI173yhx1DtKfDdFwMGjnjy66N27LU.-qQp3Q5H_KCvBmdD2U3jiCKoH7OxVmU_wUqTuttE2-HchBvzGkWsou8uYg~dcebbe62660f5d8ef5000a74a248f89e

Analysts' recommendations: GSK plc

Dec. 09	GSK : JP Morgan keeps a Sell rating	ZD
Dec. 08	JPMorgan cuts M&G, UBS cuts Trainline	AN
Dec. 08	GSK : JP Morgan gives a Sell rating	ZD
Dec. 04	GSK : UBS sticks Neutral	ZD
Dec. 04	UK stocks rise on boost from industrials and financials	RE
Dec. 02	Janux dives as gaps in prostate cancer study data worry investors	RE
Nov. 28	AnaptysBio, GSK's Tesaro Unit Likely Settle Jemperli Dispute Before July, Wedbush Says	MT
Nov. 25	Berenberg Raises Price Target on GSK to $43 From $41, Keeps Hold Rating	MT
Nov. 25	GSK : Deutsche Bank reiterates its Neutral rating	ZD
Nov. 25	Jefferies cuts Playtech to 'hold'	AN
Nov. 25	Berenberg Updates GSK Estimates as CFO Discusses FY26 Plans; Price Target Up	MT
Nov. 25	GSK : Gets a Neutral rating from Berenberg	ZD
Nov. 24	AnaptysBio Presents Opportunity Despite 'Near-Term Turbulence' Amid Legal Dispute with GSK, Wedbush Says	MT
Nov. 19	GSK : Jefferies keeps its Buy rating	ZD
Nov. 07	America's markets lose their nerve
Nov. 07	Goldman Sachs cuts Weir; UBS ups British Land	AN
Nov. 07	GSK : JP Morgan keeps a Sell rating	ZD
Nov. 05	GSK : Bernstein maintains a Buy rating	ZD
Nov. 04	GSK : Deutsche Bank remains Neutral	ZD
Nov. 04	Shore Capital cuts Next; Bernstein cuts Ryanair	AN
Oct. 31	UBS starts Drax with 'sell'; WPP targets cut	AN
Oct. 31	GSK : Jefferies gives a Buy rating	ZD
Oct. 30	GSK : DZ Bank is Neutral	ZD
Oct. 30	GSK : Deutsche Bank remains Neutral	ZD
Oct. 30	GSK : UBS gives a Neutral rating	ZD

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	GSK PLC					+2.14%
	ELI LILLY AND COMPANY					+4.69%
	JOHNSON & JOHNSON					-2.48%
	ABBVIE INC.					+9.63%
	ROCHE HOLDING AG					+2.05%
	ASTRAZENECA PLC					+12.08%
	NOVARTIS AG					+2.06%
	MERCK & CO., INC.					+7.14%
	NOVO NORDISK A/S					+22.46%
	AMGEN INC.					+2.56%
	Average					+6.23%
	Weighted average by Cap.					+5.50%

See all sector consensus

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

18.24GBP

Average target price

18.64GBP

Spread / Average Target

+2.14%

High Price Target

25.70GBP

Spread / Highest target

+40.86%

Low Price Target

14.50GBP

Spread / Lowest Target

-20.53%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

JPMORGAN	Zain Ebrahim
UBS	Matthew Weston
Berenberg Bank
BERENBERG
JEFFERIES
BERNSTEIN RESEARCH	Justin Smith
DZ BANK	Elmar Kraus
alphavalue	Abhishek Raval
DEUTSCHE BANK RESEARCH	Emmanuel Papadakis
AlphaValue/Baader Europe
Intron Health
Sadif Investment Analytics
GOLDMAN SACHS	Rajan Sharma
BNP Paribas Exane
Jefferies & Co.
Guggenheim
Citigroup
HSBC
LBBW
Bernstein
Barclays
Deutsche Bank Securities
Morgan Stanley
CREDIT SUISSE	Dominic Lunn
Bank of America Securities/Merrill Lynch
Stifel Nicolaus
ODDO BHF
Societe Generale
Liberum Capital
J.P. Morgan Chase
DEUTSCHE BANK	Emmanuel Papadakis
KEPLER CHEUVREUX	David Evans
BAADER BANK
SVB Leerink
BANK OF AMERICA (BOFA)	Graham Parry